Literature DB >> 26358272

Response to the letter to the editor entitled "Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization".

Gian Marco Tosi1, Claudio Traversi2, Elisabetta Nuti2, Davide Marigliani2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26358272     DOI: 10.1007/s00417-015-3171-3

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  5 in total

1.  Comparison of macular thickness between Cirrus HD-OCT and Stratus OCT.

Authors:  Masashi Kakinoki; Osamu Sawada; Tomoko Sawada; Hajime Kawamura; Masahito Ohji
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2009 Mar-Apr

2.  Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal neovascularization.

Authors:  C S Tan; M C Chew; T H Lim
Journal:  Eye (Lond)       Date:  2013-09-20       Impact factor: 3.775

3.  Comparison of choroidal thicknesses using swept source and spectral domain optical coherence tomography in diseased and normal eyes.

Authors:  Colin S H Tan; Wei Kiong Ngo; Kai Xiong Cheong
Journal:  Br J Ophthalmol       Date:  2014-10-01       Impact factor: 4.638

4.  Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization.

Authors:  Claudio Traversi; Elisabetta Nuti; Davide Marigliani; Gabriele Cevenini; Angelo Balestrazzi; Gianluca Martone; Tomaso Caporossi; Gian Marco Tosi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-13       Impact factor: 3.117

Review 5.  Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).

Authors:  Ursula Schmidt-Erfurth; Victor Chong; Anat Loewenstein; Michael Larsen; Eric Souied; Reinier Schlingemann; Bora Eldem; Jordi Monés; Gisbert Richard; Francesco Bandello
Journal:  Br J Ophthalmol       Date:  2014-09       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.